Latest Dopamine agonists Stories
WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while levodopa remains the gold standard for Parkinson's disease treatment, physicians say they will increasingly use other agents to delay the need for levodopa.
Pathological gambling, compulsive shopping, binge eating and other impulse control disorders appear to be more common among individuals taking dopamine agonist medications for Parkinson's disease.
LAWRENCEVILLE, N.J., April 26 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYNÂ® (carbidopa) tablets from Bristol-Myers Squibb Company (BMS).
ATLANTA, April 13 /PRNewswire/ -- New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.
ATLANTA, April 8 /PRNewswire/ -- Extensive new data on rotigotine will be presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada between April 10th and 17th, 2010. At a series of oral and poster presentations, leading international investigators will report the latest data on rotigotine in all stages of Parkinson's disease and in moderate to severe Restless Legs Syndrome (RLS). Oral presentations SP710 (5 year) Long-term Safety and Efficacy of Rotigotine in...
It has long been known that alcohol exposure is toxic to the developing fetus and can result in lifelong brain, cognitive and behavioral problems.
WALTHAM, Mass., Jan.
In a world first, researchers identify and define dopamine agonist withdrawal syndrome, or DAWS.
Clinical study seeks to validate dyskinesia clinical scales, lowering hurdle to industry investment in new treatments NEW YORK, Dec. 21 /PRNewswire-USNewswire/ -- The Michael J.
LONDON, Dec. 9 /PRNewswire/ -- The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief.